Human Insulin Drug Market Synopsis:
Human Insulin Drug Market Size Was Valued at USD 52.3 Billion in 2023, and is Projected to Reach USD 107.2 Billion by 2032, Growing at a CAGR of 8.3% From 2024-2032.
The Human Insulin Drug Market refers to products that seek to control, maintain or regulate diabetes type 1 and 2 in patients with that complication. Insulin is a bioengineered hormone that mimics the hormone produced by the human pancreas, an organ which has a primary responsibility of regulating glucose. It consists different types of insulin comprising of; rapid-acting, short-acting, intermediate-acting and long-acting insulins which are prescribed depending on the convenience of the patient. The rise in incidence of diabetes, the developments in the insulin delivery devices and systems and the augmenting consciousness of diabetes care and management are some of the key factors that defines this market.
The market of the human insulin drug is growing at the considerable rate in the last few years due to increased cases of diabetes across the world and a growing population of geriatric patients. The IDF estimated that 537 million adults were living with diabetes in 2021, and projected that number would reach 783 million by 2045. This increasing rate of occurrences makes management strategies highly important and pushes the need for human insulin products. New technologies that have impacted the product category include, insulin pens, and continuous glucose monitoring systems that also help patients to administer insulin with ease making a significant contribution to the size of the market.
Second, it must be added that the market has a high level of competition and is led by several significant companies. These players are committed to the R & D necessary to launch new insulin forms and methods of administering insulin originating from the identified players. This is the new shift towards biosimilar insulins that has gradually started picking up speed due to its affordance of cheaper copies of the original branded products hence making Insulin more available to patients. Also, numerous governments and healthcare organizations have also provided high financial trust on diabetes care programs which in turn is creating higher demand for human insulin drugs.
Human Insulin Drug Market Trend Analysis:
Growing Demand for Biosimilars
- With a growing population of diabetic patient, demand for biosimilar insulin is expected to rise due to growing biologic medical products that are highly similar to existing reference products. Biosimilars have emerged to address the increasing global demand of affordable products that garnered by often costly branded insulin products to address a growingly expensive march in diabetes management. Besides, the access of the biosimilars to the patient that improves the availability of insulin therapy also help to create better market competition, and subsequently leads to decrease in the overall cost of managing diabetes. The biosimilar regulatory approval process has also been evolving throughout the world to support the development of this segment by manufacturers. The high level of biosimilars adoption by healthcare providers and patients will likely have a tremendous impact on the Human Insulin Drug Market in the next few years.
Advancements in Insulin Delivery Technologies
- Expansion with modern technologies in the field of insulin administration makes Human Insulin Drug Market full of potential in the forecast period. Smart insulin pens, pumps and CGM systems are some of the developments that patients are using to manage their diabetes. Compared to classic technologies, these technologies are more accurate, convenient and allow immediate control of patients’ condition; patients can have better glycemic control. In addition, the incorporation of technology enabled health care platforms and telemedicine services is improving patient compliance and interaction with insulin therapy. Perhaps, the organizations investing in these technologies will leverage the competition faced by firms in the market. In a related development, technology firms and pharma companies are expected to work together to bring more advanced insulin delivery solutions to market, promising wider market prospects.
Human Insulin Drug Market Segment Analysis:
Human Insulin Drug Market is Segmented on the basis of Product Type, Type, Application, and Region.
By Product Type, Human Insulin segment is expected to dominate the market during the forecast period
- Thus the global human insulin drug market indicates that the human insulin segment is specified to rule throughout the prediction period. This can be attributed to the preferential use of human insulin formulations which have remained the mainstay of diabetic control for several years. As diabetes continues to become more the norm across advanced nations and developing countries alike, care delivery professionals are turning to human insulin as one of the primary modes of treatment for affected patients. The human insulin segment consists of regular insulin, NPH insulin, and combination regular/NPH products that allow an individual client-centered approach to managing patient needs. In addition, there is a more frequent appearance of new formulations that can be expected to propel the segment, as patients and physicians demand better glycemic control and patient outcomes.
By Type, Short Acting segment expected to held the largest share
- Short acting human insulin is anticipated to dominate the human insulin drug market share during the forecast period 2020 to 2026. That is why short-acting insulins like regular insulin are preferred for diabetes treatment because they act quickly and are easy to doses. Which makes them suitable especially for patients with conditions requiring the establishment of initial insulin control, including patients with diabetes type one or other forms of ketosis or hyperosmolar hyperglycemic state. The volunteers’ preference for short-acting insulins is due to the versatility in the supply chain, which presents the insulins in vials and the pre-filled pens. As well, anticipated future advancements in research to enhance both the effectiveness and the lack of risk associated with short-acting insulin will help the segment to continue to grow.
Human Insulin Drug Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
- By 2023, the Human Insulin Drug Market in North America is expected to capture the largest market size of 40%. Due to the increasing incidence of diabetes in the related population, developed medical environment, and enhancing healthcare expenditure in the area have driven the considerable growth of the market. Moreover, the availability of large pharma companies as well as a solid logistic base influenced by strong economic performance make North America leaders. In particular, the United States appears to have a strong market of insulin products helpful due to the corresponding reimbursement and an increasing focus on diabetes. This dominance also puts the region at the fore for defining the global market for human insulin.
Active Key Players in the Human Insulin Drug Market:
- Amgen Inc. (United States)
- AstraZeneca (United Kingdom)
- Boehringer Ingelheim (Germany)
- Bristol-Myers Squibb (United States)
- Eli Lilly and Company (United States)
- Hikma Pharmaceuticals (United Kingdom)
- Julphar (United Arab Emirates)
- Merck & Co., Inc. (United States)
- Mylan N.V. (United States)
- Novo Nordisk (Denmark)
- Pfizer Inc. (United States)
- Roche (Switzerland)
- Sanofi (France)
- Teva Pharmaceutical Industries (Israel)
- Wockhardt Ltd. (India)
- Other Active Players
|
Human Insulin Drug Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 52.3 Billion |
|
Forecast Period 2024-32 CAGR: |
8.3% |
Market Size in 2032: |
USD 107.2 Billion |
|
Segments Covered: |
By Product Type |
|
|
|
By Type |
|
||
|
By Application |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Human Insulin Drug Market by Product Type
4.1 Human Insulin Drug Market Snapshot and Growth Engine
4.2 Human Insulin Drug Market Overview
4.3 Human Insulin
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Human Insulin: Geographic Segmentation Analysis
4.4 Basal Insulin
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Basal Insulin: Geographic Segmentation Analysis
4.5 Bolus Insulin
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Bolus Insulin: Geographic Segmentation Analysis
4.6 Insulin Combinations
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Insulin Combinations: Geographic Segmentation Analysis
4.7 Biosimilar Insulins
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 Biosimilar Insulins: Geographic Segmentation Analysis
Chapter 5: Human Insulin Drug Market by Type
5.1 Human Insulin Drug Market Snapshot and Growth Engine
5.2 Human Insulin Drug Market Overview
5.3 Short Acting
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Short Acting: Geographic Segmentation Analysis
5.4 Long Acting
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Long Acting: Geographic Segmentation Analysis
Chapter 6: Human Insulin Drug Market by Application
6.1 Human Insulin Drug Market Snapshot and Growth Engine
6.2 Human Insulin Drug Market Overview
6.3 Type 1 Diabetes
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Type 1 Diabetes: Geographic Segmentation Analysis
6.4 Type 2 Diabetes
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Type 2 Diabetes: Geographic Segmentation Analysis
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 Human Insulin Drug Market Share by Manufacturer (2023)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 TEVA PHARMACEUTICAL INDUSTRIES LTD. (JERUSALEM)
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 BAYER (GERMANY)
7.4 EUROGINE (SPAIN)
7.5 COOPERSURGICAL INC. (US)
7.6 PFIZER INC. (US)
7.7 HLL LIFECARE LIMITED (THIRUVANANTHAPURAM)
7.8 OCON MEDICAL LTD. (ISRAEL)
7.9 PROSAN INTERNATIONAL BV (NETHERLANDS)
7.10 MELBEA INNOVATIONS (HUNGARY)
7.11 ALLERGAN
7.12 MERCK & CO. INC. (US)
7.13 DKT INTERNATIONAL (US)
7.14 MEDISAFE DISTRIBUTION INC. (CANADA)
7.15 MEDICINES360 (US)
7.16 PREGNA INTERNATIONAL LIMITED (INDIA)
7.17 EGEMEN INTERNATIONAL (TURKEY)
7.18 OTHER ACTIVE PLAYERS
Chapter 8: Global Human Insulin Drug Market By Region
8.1 Overview
8.2. North America Human Insulin Drug Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size By Product Type
8.2.4.1 Human Insulin
8.2.4.2 Basal Insulin
8.2.4.3 Bolus Insulin
8.2.4.4 Insulin Combinations
8.2.4.5 Biosimilar Insulins
8.2.5 Historic and Forecasted Market Size By Type
8.2.5.1 Short Acting
8.2.5.2 Long Acting
8.2.6 Historic and Forecasted Market Size By Application
8.2.6.1 Type 1 Diabetes
8.2.6.2 Type 2 Diabetes
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3. Eastern Europe Human Insulin Drug Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size By Product Type
8.3.4.1 Human Insulin
8.3.4.2 Basal Insulin
8.3.4.3 Bolus Insulin
8.3.4.4 Insulin Combinations
8.3.4.5 Biosimilar Insulins
8.3.5 Historic and Forecasted Market Size By Type
8.3.5.1 Short Acting
8.3.5.2 Long Acting
8.3.6 Historic and Forecasted Market Size By Application
8.3.6.1 Type 1 Diabetes
8.3.6.2 Type 2 Diabetes
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Russia
8.3.7.2 Bulgaria
8.3.7.3 The Czech Republic
8.3.7.4 Hungary
8.3.7.5 Poland
8.3.7.6 Romania
8.3.7.7 Rest of Eastern Europe
8.4. Western Europe Human Insulin Drug Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size By Product Type
8.4.4.1 Human Insulin
8.4.4.2 Basal Insulin
8.4.4.3 Bolus Insulin
8.4.4.4 Insulin Combinations
8.4.4.5 Biosimilar Insulins
8.4.5 Historic and Forecasted Market Size By Type
8.4.5.1 Short Acting
8.4.5.2 Long Acting
8.4.6 Historic and Forecasted Market Size By Application
8.4.6.1 Type 1 Diabetes
8.4.6.2 Type 2 Diabetes
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 The Netherlands
8.4.7.5 Italy
8.4.7.6 Spain
8.4.7.7 Rest of Western Europe
8.5. Asia Pacific Human Insulin Drug Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size By Product Type
8.5.4.1 Human Insulin
8.5.4.2 Basal Insulin
8.5.4.3 Bolus Insulin
8.5.4.4 Insulin Combinations
8.5.4.5 Biosimilar Insulins
8.5.5 Historic and Forecasted Market Size By Type
8.5.5.1 Short Acting
8.5.5.2 Long Acting
8.5.6 Historic and Forecasted Market Size By Application
8.5.6.1 Type 1 Diabetes
8.5.6.2 Type 2 Diabetes
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6. Middle East & Africa Human Insulin Drug Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size By Product Type
8.6.4.1 Human Insulin
8.6.4.2 Basal Insulin
8.6.4.3 Bolus Insulin
8.6.4.4 Insulin Combinations
8.6.4.5 Biosimilar Insulins
8.6.5 Historic and Forecasted Market Size By Type
8.6.5.1 Short Acting
8.6.5.2 Long Acting
8.6.6 Historic and Forecasted Market Size By Application
8.6.6.1 Type 1 Diabetes
8.6.6.2 Type 2 Diabetes
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkiye
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7. South America Human Insulin Drug Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size By Product Type
8.7.4.1 Human Insulin
8.7.4.2 Basal Insulin
8.7.4.3 Bolus Insulin
8.7.4.4 Insulin Combinations
8.7.4.5 Biosimilar Insulins
8.7.5 Historic and Forecasted Market Size By Type
8.7.5.1 Short Acting
8.7.5.2 Long Acting
8.7.6 Historic and Forecasted Market Size By Application
8.7.6.1 Type 1 Diabetes
8.7.6.2 Type 2 Diabetes
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
|
Human Insulin Drug Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 52.3 Billion |
|
Forecast Period 2024-32 CAGR: |
8.3% |
Market Size in 2032: |
USD 107.2 Billion |
|
Segments Covered: |
By Product Type |
|
|
|
By Type |
|
||
|
By Application |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
